COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

被引：0

作者：

Minshall, M. E. ^{[1
]}

Sauriol, L. ^{[2
]}

机构：

[1] IMS Hlth, Noblesville, IN USA

[2] Sanofi Aventis, Laval, PQ, Canada

来源：

VALUE IN HEALTH | 2008年 / 11卷 / 06期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A502 / A502

页数：1

共 50 条

[1] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in the Canadian payer setting
Kapor, Jovana
Minshall, Michael E.
Tunis, Sandra L.
Conner, Chris
Mccormick, John
Seager, Christine
Groleau, Danielle
[J]. DIABETES, 2008, 57 : A98 - A98
[2] Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada
Tunis S.L.
Sauriol L.
Minshall M.E.
[J]. Applied Health Economics and Health Policy, 2010, 8 (4) : 267 - 280
[3] Efficacy and safety of insulin glargine added to ongoing therapy with multiple oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus (T2DM)
Raskin, P.
Tanenberg, R. J.
Vlajnic, A.
Hollander, P.
[J]. DIABETOLOGIA, 2007, 50 : S405 - S406
[4] Cost-effectiveness of insulin detemir compared to NPH insulin for type 2 diabetes mellitus (T2DM) in the Canadian payer setting: Modeling analysis using an observational study
Minshall, M. E.
Tunis, S. L.
Conner, C.
McCormick, J., I
Kapor, J.
Groleau, D.
[J]. VALUE IN HEALTH, 2008, 11 (03) : A224 - A224
[5] Efficacy and safety of insulin glargine added to ongoing therapy with multiple oral antidiabetic drugs (OADs) in patients with type 2 diabetes mellitus (T2DM)
Davidson, Mayer B.
Raskin, Philip
Tanenberg, Robert
Vlajnic, Aleksandra
Hollander, Priscilla
[J]. DIABETES, 2007, 56 : A542 - A542
[6] Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naive Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
Shafie, Asrul Akmal
Ng, Chin Hui
[J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2020, 12 : 333 - 343
[7] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
Tunis, Sandra L.
Minshall, Michael E.
Conner, Christopher
McCormick, John I.
Kapor, Jovana
Yale, Jean-Francois
Groleau, Danielle
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
[8] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
Sanchez-Covisa, J.
Capel, M.
Schmidt, R.
Charokopou, M.
Verheggen, B. G.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
[9] COST-EFFECTIVENESS OF SAXAGLIPTIN COMPARED TO SITAGLIPTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
Hutchings, A.
Tolley, K.
Achana, F.
Brereton, N. J.
Lebmeier, M.
Mesa, O. A.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A478 - A478
[10] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
Kolasa, K.
Niewada, M.
de Troconiz, J. Puelles Fernandez
Townsend, R.
McEwan, P.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A290 - A290

← 1 2 3 4 5 →